- Complete panel for the detection of the Mumps infection (Mumps IgG, Mumps IgM)
- Cartridge optimized for laboratory routine testing
- High specificity and sensitivity of the IgG and IgM kits
The Mumps IgM test is an immunological chemiluminescent (CLIA) test for the quantity determination of the specific IgM class antibodies against the Mumps virus in serum and plasma (K3-EDTA, heparin sodium and sodium citrate) samples, using IDS automated analyzers.
This dosage is used as a diagnostic aid in the assessment of the immune status of the patient with reference to infection by the Mumps virus.
Mumps is a contagious, acute pathology of viral aetiology caused by the Mumps virus, an RNA virus belonging to the Rubulavirus genus of the Paramyxoviridae family(1). The virus was first isolated in saliva and is able to infect various tissues including the parotid glands and salivary glands in the area under the ears and behind the jaws, causing an acute systemic inflammation(2).
The Mumps virus is transmitted by the respiratory route through the Flügge droplets of infected individuals. The contagious period ranges from the 3 days before to the 4 days after the onset of Mumps with an infectivity peak in the 48 hours preceding the appearance of the pathology. The incubation period is variable, usually 16-18 days. The premonitory symptoms are rather non-specific and include myalgia, anorexia, malaise, headache, swelling and pain in the neck under the ears accompanied by a not very high temperature(1). The swelling of the parotid glands is the commonest symptom and appears in 30-40% of the affected population on one or both sides. After natural infection, the individual is immune for all their life as a result of the specific humoral and cellular immune response.
When there is no glandular swelling and an aetiological diagnosis of other clinical symptoms is necessary without signs of Mumps (e.g. meningitis, encephalitis, orchitis and oophoritis), laboratory confirmation is requested through serological tests.
IgM can be detected in serum in the first 3-4 days after the appearance of clinical symptoms, reaching a peak around the first week from onset and continuing for 8-12 weeks. As for measles and German measles, the IgM can be transient or even absent in people who were given a dose of trivalent or quadrivalent vaccine(4). IgG antibodies appear within 7-10 days of the onset and continue at high levels for years. The ability to detect the IgM is serum is high in patients who have never been vaccinated, intermediate for those with a single dose of vaccine and very low for those who received two doses.
Evidence of acute infection is obtained by showing the existence of IgM antibodies in the serum immediately after the onset of the symptoms and later by detecting a significant increase in the IgG tire in two sera, taken in the acute stage and convalescence respectively. Reinfection after a vaccination is recognised by high titres of IgG mostly without IgM(8).
Center for Disease Control and Prevention (CDC). Mumps.. In: Atkinson, W.; Wolfe, S.; Hamborsky, J., editors. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed.. Public Health Foundation; Washington, DC: 2011. p. 205-214
2. Hviid A, Rubin S, Muhlemann K. Mumps. Lancet 2008;371(9616):932–44
3. American Academy of Pediatrics. Mumps. In: Pickering LK, et al, editors. Red Book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 468–72
4. Immunisation against infectious disease – ‘The Green Book’ – chapter 21 2006 Edition
5. Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink book, 12th ed. Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011.
6. Centers for Disease Control and Prevention. Mumps—United States, 1980–1983. MMWR Morb Mortal Wkly Rep 1983; 32:545–7
7. Galazka AM, Robertson SE, Kraigher A. Mumps and Mumps vaccine: a global review. Bull World Health Organ 1999;77:3-14
8. Burzio V et al, Diagnosi differenziale delle tumefazioni parotidee in età pediatrica: un caso clinico Bollettino della Società Medico Chirurgica di Pavia; 2010, 123(2):407-412.